Greg Harrison
Stock Analyst at B of A Securities
(2.22)
# 2,673
Out of 4,876 analysts
86
Total ratings
44.62%
Success rate
-3.74%
Average return
Main Sectors:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Neutral | $321 → $315 | $284.09 | +10.88% | 3 | Jun 11, 2025 | |
| VERA Vera Therapeutics | Maintains: Sector Outperform | $65 → $55 | $23.29 | +136.15% | 2 | Jun 2, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Sector Outperform | $51 → $19 | $2.59 | +633.59% | 6 | May 28, 2025 | |
| LQDA Liquidia | Maintains: Sector Outperform | $36 → $37 | $12.83 | +188.39% | 6 | May 28, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Initiates: Sector Outperform | $32 | $14.41 | +122.07% | 1 | May 28, 2025 | |
| KROS Keros Therapeutics | Maintains: Sector Outperform | $41 → $26 | $13.51 | +92.45% | 5 | May 12, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $28 → $20 | $18.40 | +8.70% | 4 | May 8, 2025 | |
| GERN Geron | Downgrades: Sector Perform | $4 → $1.5 | $1.53 | -1.96% | 3 | May 8, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $450 → $442 | $443.40 | -0.32% | 6 | May 6, 2025 | |
| AGIO Agios Pharmaceuticals | Maintains: Sector Outperform | $74 → $71 | $33.65 | +111.00% | 5 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $52 → $55 | $45.12 | +21.90% | 6 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $338 → $342 | $318.25 | +7.46% | 5 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $40 | $17.14 | +133.37% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $73 → $75 | $54.13 | +38.56% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $27 → $32 | $15.13 | +111.50% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $18 | $10.37 | +73.58% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $22 | $9.46 | +132.56% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $89 → $91 | $9.61 | +846.93% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $11.84 | +1.35% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $0.56 | +169.15% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $39 | $14.00 | +178.57% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $15 | $2.12 | +607.55% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $3.32 | -9.64% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $2.11 | +3,217.54% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $8 | $29.64 | -73.01% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $18.01 | +199.83% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $270 → $90 | $29.68 | +203.23% | 5 | Mar 14, 2022 |
United Therapeutics
Jun 11, 2025
Maintains: Neutral
Price Target: $321 → $315
Current: $284.09
Upside: +10.88%
Vera Therapeutics
Jun 2, 2025
Maintains: Sector Outperform
Price Target: $65 → $55
Current: $23.29
Upside: +136.15%
Rocket Pharmaceuticals
May 28, 2025
Maintains: Sector Outperform
Price Target: $51 → $19
Current: $2.59
Upside: +633.59%
Liquidia
May 28, 2025
Maintains: Sector Outperform
Price Target: $36 → $37
Current: $12.83
Upside: +188.39%
Arcturus Therapeutics Holdings
May 28, 2025
Initiates: Sector Outperform
Price Target: $32
Current: $14.41
Upside: +122.07%
Keros Therapeutics
May 12, 2025
Maintains: Sector Outperform
Price Target: $41 → $26
Current: $13.51
Upside: +92.45%
Apellis Pharmaceuticals
May 8, 2025
Maintains: Sector Perform
Price Target: $28 → $20
Current: $18.40
Upside: +8.70%
Geron
May 8, 2025
Downgrades: Sector Perform
Price Target: $4 → $1.5
Current: $1.53
Upside: -1.96%
Vertex Pharmaceuticals
May 6, 2025
Maintains: Sector Perform
Price Target: $450 → $442
Current: $443.40
Upside: -0.32%
Agios Pharmaceuticals
May 2, 2025
Maintains: Sector Outperform
Price Target: $74 → $71
Current: $33.65
Upside: +111.00%
Apr 30, 2025
Maintains: Sector Outperform
Price Target: $52 → $55
Current: $45.12
Upside: +21.90%
Mar 31, 2025
Maintains: Sector Outperform
Price Target: $338 → $342
Current: $318.25
Upside: +7.46%
Mar 10, 2025
Upgrades: Sector Outperform
Price Target: $40
Current: $17.14
Upside: +133.37%
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $73 → $75
Current: $54.13
Upside: +38.56%
Feb 12, 2025
Maintains: Sector Outperform
Price Target: $27 → $32
Current: $15.13
Upside: +111.50%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $10.37
Upside: +73.58%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $22
Current: $9.46
Upside: +132.56%
Jun 13, 2023
Maintains: Buy
Price Target: $89 → $91
Current: $9.61
Upside: +846.93%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $11.84
Upside: +1.35%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $0.56
Upside: +169.15%
Mar 7, 2023
Initiates: Buy
Price Target: $39
Current: $14.00
Upside: +178.57%
Nov 18, 2022
Maintains: Neutral
Price Target: $18 → $15
Current: $2.12
Upside: +607.55%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $3.32
Upside: -9.64%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $2.11
Upside: +3,217.54%
Jun 8, 2022
Upgrades: Neutral
Price Target: $8
Current: $29.64
Upside: -73.01%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $18.01
Upside: +199.83%
Mar 14, 2022
Downgrades: Underperform
Price Target: $270 → $90
Current: $29.68
Upside: +203.23%